Table 1.
Demographics and baseline characteristics
| All patients (n = 40) | |
|---|---|
| Age, years, median (range) | 62 (41–73) |
| < 65 | 27 (67.5) |
| ≥ 65 | 13 (32.5) |
| Sex | |
| Male | 36 (90.0) |
| Female | 4 (10.0) |
| ECOG performance status | |
| 0 | 4 (10.0) |
| 1 | 36 (90.0) |
| Smoking statusa | |
| Never | 9 (22.5) |
| Current | 2 (5.0) |
| Former | 25 (62.5) |
| Histologic type | |
| Squamous carcinoma | 17 (42.5) |
| Non-squamous carcinoma | 23 (57.5) |
| Presence of metastases | 39 (97.5) |
| Brain metastases | |
| Yes | 2 (5.0) |
| No | 38 (95.0) |
| Liver metastases | |
| Yes | 3 (7.5) |
| No | 37 (92.5) |
| No. of prior systemic therapy | |
| 1 | 23 (57.5) |
| 2 | 17 (42.5) |
| PD-L1 TPSb | |
| < 1% | 27 (67.5) |
| ≥ 1% | 11 (27.5) |
| 1–49% | 6 (15.0) |
| ≥ 50% | 5 (12.5) |
| tTMBb | |
| Low (< 10 mutations/Mb) | 7 (17.5) |
| High (≥ 10 mutations/Mb) | 17 (42.5) |
Data are n (%) unless otherwise indicated
ECOG, Eastern Cooperative Oncology Group; PD-L1, programmed death-ligand 1; TPS, tumor proportion score; tTMB, tissue tumor mutational burden
aData were missing for the remaining patients
bA mandatory fresh biopsy or archival tissue for PD-L1 TPS or tTMB was not requested at enrollment